Aflibercept is under clinical development by Regeneron Pharmaceuticals and currently in Phase III for Age Related Macular Degeneration. According to GlobalData, Phase III drugs for Age Related Macular Degeneration have a 55% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Aflibercept’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Aflibercept (Eylea) is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1. Eylea is formulated as an iso-osmotic injection solution for intravitreal route of administration. Eylea is indicated for treatment of neovascular (wet) age-related macular degeneration (wet AMD) and for the treatment of macular edema following central retinal vein occlusion. It is also indicated for non-proliferative diabetic retinopathy (NPDR), diabetic macular edema(DME) and Diabetic Retinopathy (DR) in Patients with DME, for the treatment of choroidal neovascularization and macular edema secondary to branch retinal vein occlusion (BRVO), for the treatment of visual impairment due to myopic choroidal neovascularization (myopic CNV), and all stages of non-proliferative diabetic retinopathy (DR), and thereby reduce the risk of blindness. It is based on trap technology.
Aflibercept is under development for the treatment of retinopathy of prematurity (ROP), diabetic retinopathy, radiation retinopathy including maculopathy, optic neuropathy, non-proliferative diabetic retinopathy (NPDR), acute thyroid eye disease and diabetic macular edema at high dose. The drug candidate was also under development for the treatment of corneal neovascularization. It is administered through intravitreal or parenteral or subconjunctival as a solution form.
Regeneron Pharmaceuticals overview
Regeneron Pharmaceuticals (Regeneron) is engaged in discovering, developing, manufacturing, and marketing medicines for the treatment of serious medical conditions. Its products are focused on helping patients suffering from cancer, allergic and inflammatory diseases, eye diseases, metabolic and cardiovascular diseases, infectious diseases, neuromuscular diseases, hematologic conditions, pain, and rare diseases. It develops products using its Trap and VelociSuite technology platforms, which include VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, and other related technologies. The company operates manufacturing facilities in Rensselaer, New York, and Limerick, Ireland. It also collaborates with strategic partners to develop, manufacture, and commercialize its products. It sells its products to specialty pharmacies and distributors. The company operates in the US, the Netherlands, Bermuda, Ireland, Spain, India, Japan, and the UK. Regeneron is headquartered in Tarrytown, New York, the US.
For a complete picture of Aflibercept’s drug-specific PTSR and LoA scores, buy the report here.